

**Webtable 1a: Age and smoking (current vs. not current) adjusted hazard ratios (HR) with 95% confidence intervals (CI) for cancer mortality (selected sites) before and after additional adjustment for drinking status (not current vs. current alcohol intake) in participants with complete data on covariates (smoking  $n = 377\ 527$ ; smoking and drinking  $n = 365\ 557$ ; data left censored at 3 years) in the Asia Pacific Cohort Studies Collaboration. Models stratified by study and sex.**

Cancer site	Covariates**		Body mass index (kg/m <sup>2</sup> )				Trend $\geq 18.5$ (kg/m <sup>2</sup> )	
			12.0-18.4	18.5-24.9	25.0-29.9	30.0-60.0	Per 5 units	$P_{trend}$
All Cancer*	SMK	Events	176	1971	1130	364		
		HR (95% CI)	1.12 (0.96, 1.31)	1.00 (0.96, 1.05)	1.07 (1.01, 1.14)	1.22 (1.09, 1.36)	1.09 (1.04, 1.14)	0.002
	SMK, ALC	Events	159	1730	1023	347		
		HR (95% CI)	1.16 (0.98, 1.37)	1.00 (0.95, 1.05)	1.08 (1.02, 1.16)	1.23 (1.10, 1.38)	1.09 (1.04, 1.15)	0.001
UADT	SMK	Events	18	166	53	12		
		HR (95% CI)	1.00 (0.61, 1.66)	1.00 (0.85, 1.18)	0.71 (0.54, 0.94)	0.68 (0.38, 1.23)	0.77 (0.61, 0.97)	0.06
	SMK, ALC	Events	18	156	50	12		
		HR (95% CI)	1.10 (0.66, 1.82)	1.00 (0.85, 1.18)	0.68 (0.51, 0.91)	0.67 (0.37, 1.22)	0.76 (0.60, 0.96)	0.047
Oesophagus	SMK	Events	14	98	29	7		
		HR (95% CI)	1.17 (0.66, 2.08)	1.00 (0.81, 1.24)	0.76 (0.52, 1.10)	0.79 (0.36, 1.71)	0.85 (0.64, 1.15)	0.30
	SMK, ALC	Events	14	94	26	7		
		HR (95% CI)	1.24 (0.70, 2.21)	1.00 (0.81, 1.24)	0.69 (0.46, 1.02)	0.77 (0.36, 1.69)	0.82 (0.61, 1.12)	0.21
Oropharynx, larynx	SMK	Events	4	68	24	5		
		HR (95% CI)	0.68 (0.24, 1.89)	1.00 (0.78, 1.28)	0.65 (0.43, 0.98)	0.56 (0.23, 1.41)	0.66 (0.46, 0.95)	0.09

Cancer site	Covariates**	Body mass index (kg/m <sup>2</sup> )				Trend ≥ 18.5 (kg/m <sup>2</sup> )		
		12.0-18.4	18.5-24.9	25.0-29.9	30.0-60.0	Per 5 units	<i>P</i> <sub>trend</sub>	
Lung	SMK, ALC	Events	4	62	24	5		
		HR (95% CI)	0.78 (0.28, 2.20)	1.00 (0.77, 1.29)	0.68 (0.45, 1.03)	0.57 (0.23, 1.42)	0.67 (0.47, 0.97)	0.12
	SMK	Events	71	544	192	64		
		HR (95% CI)	1.13 (0.88, 1.47)	1.00 (0.92, 1.09)	0.69 (0.60, 0.80)	0.85 (0.65, 1.10)	0.86 (0.77, 0.97)	0.006
SMK, ALC	Events	68	527	177	63			
	HR (95% CI)	1.10 (0.84, 1.43)	1.00 (0.92, 1.09)	0.66 (0.57, 0.77)	0.83 (0.64, 1.08)	0.86 (0.76, 0.96)	0.003	

\*All cancers after excluding lung and upper aero-digestive tract cancers. \*\*In addition to age: SMK = smoking and ALC = drinking status

**Webtable 1b: Age adjusted hazard ratios (HR) with 95% confidence intervals (CI) for cancer mortality (selected sites) according to body mass index in never smokers (NEVER SMK,  $n = 172\ 268$ ) compared to ever, ex, or current smokers (SMOKER,  $n = 168\ 228$ ) after left censoring at 3 years in the Asia Pacific Cohort Studies Collaboration. Models stratified by study and sex.**

Cancer site	Smoking		Body mass index (kg/m <sup>2</sup> )				Trend $\geq 18.5$ (kg/m <sup>2</sup> )		
			12.0-18.4	18.5-24.9	25.0-29.9	30.0-60.0	Per 5 units	$P_{trend}$	$P_{smoke}$
All Cancer*	NEVER SMK	Events	41	674	448	178			
		HR (95% CI)	0.88 (0.64, 1.21)	1.00 (0.93, 1.08)	1.07 (0.98, 1.18)	1.28 (1.09, 1.49)	1.11 (1.03, 1.19)	0.007	0.53
	SMOKER	Events	74	932	602	170			
		HR (95% CI)	1.11 (0.87, 1.41)	1.00 (0.94, 1.07)	1.09 (1.00, 1.18)	1.13 (0.97, 1.33)	1.08 (1.01, 1.15)	0.08	
UADT	NEVER SMK	Events	1	27	20	4			
		HR (95% CI)	0.52 (0.07, 3.80)	1.00 (0.69, 1.45)	1.17 (0.75, 1.83)	0.89 (0.32, 2.43)	1.10 (0.76, 1.59)	0.91	0.009
	SMOKER	Events	7	89	28	7			
		HR (95% CI)	1.05 (0.48, 2.32)	1.00 (0.81, 1.24)	0.54 (0.37, 0.79)	0.56 (0.26, 1.21)	0.59 (0.43, 0.81)	0.01	
Oesophagus	NEVER SMK	Events	0	15	8	3			
		HR (95% CI)	-	1.00 (0.61, 1.65)	0.82 (0.40, 1.65)	1.05 (0.32, 3.40)	1.09 (0.66, 1.80)	0.88	0.39
	SMOKER	Events	5	39	17	4			
		HR (95% CI)	1.82 (0.70, 4.75)	1.00 (0.73, 1.37)	0.79 (0.48, 1.29)	0.85 (0.30, 2.35)	0.83 (0.55, 1.26)	0.51	
Oropharynx, larynx	NEVER SMK	Events	1	12	12	1			
		HR (95% CI)	1.16 (0.16, 8.58)	1.00 (0.57, 1.75)	1.62 (0.91, 2.89)	0.57 (0.08, 4.19)	1.09 (0.63, 1.91)	0.76	0.005
	SMOKER	Events	2	50	11	3			

Cancer site	Smoking	Body mass index (kg/m <sup>2</sup> )				Trend $\geq$ 18.5 (kg/m <sup>2</sup> )			
		12.0-18.4	18.5-24.9	25.0-29.9	30.0-60.0	Per 5 units	<i>P</i> <sub>trend</sub>	<i>P</i> <sub>smoke</sub>	
Lung**		HR (95% CI)	0.51 (0.12, 2.15)	1.00 (0.75, 1.34)	0.36 (0.20, 0.65)	0.37 (0.11, 1.18)	0.41 (0.26, 0.66)	0.005	
	NEVER SMK	Events	14	78	20	11			
		HR (95% CI)	2.04 (1.18, 3.53)	1.00 (0.80, 1.25)	0.42 (0.27, 0.65)	0.71 (0.39, 1.31)	0.78 (0.60, 1.02)	0.01	0.83
	SMOKER	Events	36	397	156	50			
		HR (95% CI)	0.85 (0.60, 1.21)	1.00 (0.91, 1.10)	0.67 (0.57, 0.79)	0.78 (0.58, 1.05)	0.81 (0.71, 0.92)	0.004	

\*All cancers after excluding lung and upper aero-digestive tract cancers. \*\*HR with 95% CI presented in Figure 2.

**Webtable 2: Baseline summary statistics and details of the 39 cohorts included in the analyses of body mass index and site-specific cancer mortality in the Asia Pacific Cohort Studies Collaboration (APCSC)\***

Country	Study	Baseline	No. of subjects	No. of cancer deaths	Follow-up (yrs) Median	Female (%)	Age (yrs)		Body mass index (kg/m <sup>2</sup> )				Smokers	
							Mean	Range	Mean	SD	Mean	SD	Males %	Females %
Australia	Busselton	1966-1981	7423	689	26.5	52	44.7	20 - 96	24.9	3.2	24.4	4.2	45	24
Australia	Longitudinal Study of Aging	1992-1993	1505	66	5.1	48	78.0	65 - 104	25.8	3.5	26.2	4.5	7	7
Australia	Melbourne	1990-1994	41264	1112	8.5	59	54.8	27 - 75	27.2	3.6	26.7	4.9	15	9
Australia	National Heart Foundation	1989-1990	9257	154	8.3	51	43.4	20 - 70	25.9	3.6	24.9	4.8	27	21
Australia	Newcastle	1983-1994	5926	215	8.9	50	51.7	21 - 77	27.1	3.8	26.3	5.1	28	18
Australia	Perth	1978-1994	10225	311	14.4	48	45.1	20 - 90	25.7	3.4	24.7	4.4	30	21
Australia	WA AAA Screenees	1996-1999	12193	400	3.2	0	72.2	65 - 84	26.9	3.7	-	-	11	-
New Zealand	Fletcher Challenge	1992-1994	10339	134	5.8	28	44.3	20 - 89	26.9	4.0	25.2	4.5	26	18
<b>ANZ</b>	<b>Subtotal</b>	<b>1966-1999</b>	<b>98132</b>	<b>3081</b>	<b>8.3</b>	<b>45</b>	<b>53.2</b>	<b>20 - 104</b>	<b>26.6</b>	<b>3.7</b>	<b>26.0</b>	<b>4.9</b>	<b>20</b>	<b>14</b>
China	Anzhen	1991	8373	66	4.3	55	53.8	35 - 92	23.6	3.3	24.1	4.0	51	10
China	Beijing Aging	1992	2084	48	4.8	51	69.8	55 - 93	22.8	3.7	23.7	4.2	46	14

China	CISCH	1992-1993	2165	3	3.3	51	44.2	34 - 64	24.8	3.1	24.5	3.8	55	1
China	Capital Iron & Steel Company	1974-1980	5031	104	12.5	0	45.3	20 - 74	23.2	2.7	-	-	74	-
China	East Beijing	1977-1994	1083	15	17.1	52	43.2	20 - 84	23.5	3.0	23.7	3.5	49	11
China	Fangshan	1991-1992	2607	8	3.6	67	47.3	34 - 86	23.7	3.2	24.8	3.7	74	21
China	Guangzhou Occupational	1985-1997	20543	127	7.5	32	42.4	29 - 87	22.4	2.8	22.9	3.3	70	1
China	Huashan	1991-1992	1640	4	2.9	54	52.7	35 - 75	23.0	3.2	23.6	3.6	49	4
China	Seven Cities Cohorts	1987	10760	175	2.7	54	53.8	35 - 96	22.3	3.3	22.9	3.9	57	17
China	Six Cohorts	1982-1986	19363	380	9.0	47	44.7	35 - 59	21.1	2.3	21.3	2.9	76	12
China	Tianjin	1984	9268	296	6.1	51	54.5	35 - 98	23.3	3.6	23.7	4.3	63	39
China	Yunnan	1992	6580	239	4.5	3	55.8	35 - 84	21.5	2.9	23.7	3.0	70	0
Hong Kong	Hong Kong	1985-1991	2806	124	2.5	57	78.4	66 - 107	21.5	3.5	22.2	4.1	30	11
Taiwan	CVDFACTS	1988-1996	5714	65	6.0	55	47.2	20 - 92	23.6	3.2	23.4	3.5	48	1
Taiwan	Kinmen	1993-1995	1191	30	2.9	47	62.8	50 - 93	22.9	2.9	24.1	3.7	52	6
Japan	Aito Town	1980-1983	1711	62	15.2	57	51.0	21 - 77	22.3	2.7	22.9	3.2	66	2

Japan	Akabane	1985- 1986	1824	55	11.0	56	54.5	40 - 69	22.2	2.7	22.7	3.2	62	1
Japan	Civil Service Workers	1990- 1992	9315	61	6.7	33	46.7	40 - 55	22.6	2.7	22.2	2.8	51	11
Japan	Hisayama	1961	1507	189	24.6	56	55.9	40 - 91	21.5	2.3	21.7	2.9	77	17
Japan	Konan	1987- 1995	1194	25	6.4	55	51.8	20 - 96	21.9	2.9	21.9	3.1	62	5
Japan	Miyama	1988- 1990	1033	35	6.6	55	60.4	40 - 80	21.8	2.7	22.4	3.2	58	7
Japan	Ohasama	1992- 1993	2196	30	4.1	63	59.3	27 - 91	22.9	2.9	23.5	3.3	51	2
Japan	Saitama	1986- 1990	3600	145	11.0	62	54.5	20 - 94	22.2	2.8	22.5	3.0	63	8
Japan	Shibata	1977	2328	207	20.0	58	56.7	40 - 89	22.0	2.6	22.8	3.3	72	4
Japan	Shigaraki Town	1991- 1997	3737	55	4.4	59	57.1	29 - 95	22.2	2.9	22.7	3.2	59	8
Japan	Shirakawa	1974- 1979	4639	164	17.5	54	48.0	20 - 67	21.3	2.6	21.6	2.9	70	5
Japan	Tanno/Soubetsu	1977	1976	86	16.4	53	51.1	39 - 65	23.0	2.7	24.2	3.4	71	10
S. Korea	KMIC	1992	183376	1232	4.0	37	44.1	35 - 59	23.4	2.4	22.3	2.5	58	0
Singapore	Singapore Heart	1982- 1997	2312	35	14.6	49	40.6	20 - 89	23.1	3.8	24.0	4.8	40	3
Singapore	Singapore NHS92	1992	3303	22	6.2	52	39.2	20 - 70	23.3	3.8	23.2	4.5	35	3
Thailand	EGAT	1985	3128	43	11.4	23	42.6	35 - 54	23.2	3.1	22.8	3.2	54	6
<b>Asia</b>	<b>Subtotal</b>	<b>1961- 1997</b>	<b>326387</b>	<b>4130</b>	<b>4.0</b>	<b>40</b>	<b>46.6</b>	<b>20 - 107</b>	<b>23.0</b>	<b>2.7</b>	<b>22.6</b>	<b>3.1</b>	<b>60</b>	<b>6</b>

<b>Overall</b>	<b>Total</b>	<b>1961- 1999</b>	<b>424519</b>	<b>7211</b>	<b>4.0</b>	<b>41</b>	<b>48.1</b>	<b>20 - 107</b>	<b>23.8</b>	<b>3.3</b>	<b>23.4</b>	<b>3.9</b>	<b>51</b>	<b>8</b>
----------------	--------------	-----------------------	---------------	-------------	------------	-----------	-------------	---------------------	-------------	------------	-------------	------------	-----------	----------

---

\*Hyphened cells denote that no data were available. Abbreviations: ANZ, Australia and New Zealand; SD, standard deviation.

Study abbreviations: WA AAA Sreenees, Western Australian Abdominal Aortic Aneurysm Screening Program; CISCH, Capital Iron and Steel Company Hospital Cohort; CVDFACTS, Cardiovascular Disease Risk Factors Two-Township Study; KMIC, Korean Medical Insurance Company; Singapore NHS92, Singapore National Health Survey 1992; EGAT, Electricity Generating Authority of Thailand

**Webtable 3: Age and smoking-adjusted HRs for cancer mortality according to BMI, with no left censoring of data (n = 424 519)\***

	BMI (kg/m <sup>2</sup> )				Trend ≥18.5 (kg/m <sup>2</sup> )	
	12.0–18.4	18.5–24.9	25.0–29.9	30.0–60.0	Per 5 units	
Cancer site	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	P <sub>trend</sub>
All cancer	1.25 (1.13–1.38)	1.00 (0.97–1.03)	0.94 (0.90–0.98)	1.03 (0.95–1.12)	1.00 (0.97–1.04)	0.62
All cancer†	1.18 (1.04–1.33)	1.00 (0.96–1.04)	1.01 (0.96–1.06)	1.12 (1.02–1.23)	1.05 (1.01–1.10)	0.09
UADT	1.52 (1.08–2.15)	1.00 (0.87–1.14)	0.83 (0.68–1.03)	0.67 (0.41–1.10)	0.82 (0.68–0.99)	0.09
Oesophagus	1.39 (0.89–2.16)	1.00 (0.84–1.20)	1.05 (0.80–1.37)	0.93 (0.51–1.69)	1.00 (0.80–1.25)	0.99
Oropharynx–larynx	1.79 (1.03–3.12)	1.00 (0.82–1.23)	0.61 (0.43–0.86)	0.39 (0.16–0.97)	0.60 (0.44–0.82)	0.009
Stomach	1.31 (1.02–1.67)	1.00 (0.91–1.09)	0.89 (0.77–1.03)	0.99 (0.69–1.44)	0.98 (0.86–1.11)	0.41
Large intestine	0.78 (0.48–1.27)	1.00 (0.90–1.12)	1.20 (1.05–1.37)	1.48 (1.20–1.83)	1.13 (1.02–1.25)	0.001
Colon	0.67 (0.33–1.39)	1.00 (0.87–1.15)	1.13 (0.96–1.33)	1.45 (1.13–1.86)	1.14 (1.01–1.29)	0.02
Rectum	0.93 (0.48–1.79)	1.00 (0.83–1.20)	1.28 (1.03–1.60)	1.44 (0.96–2.16)	1.07 (0.89–1.29)	0.07
Liver	1.23 (0.93–1.64)	1.00 (0.91–1.10)	1.00 (0.86–1.17)	1.07 (0.69–1.66)	1.07 (0.94–1.22)	0.79
Pancreas	0.71 (0.38–1.31)	1.00 (0.86–1.16)	0.93 (0.75–1.15)	0.75 (0.48–1.18)	0.93 (0.78–1.11)	0.24
Lung	1.30 (1.08–1.56)	1.00 (0.94–1.07)	0.72 (0.64–0.80)	0.81 (0.66–1.00)	0.87 (0.79–0.94)	0.0005
Skin, melanoma	1.91 (0.45–8.05)	1.00 (0.75–1.33)	0.58 (0.40–0.85)	0.75 (0.44–1.30)	0.95 (0.71–1.27)	0.15
Breast, female <60 years	0.19 (0.03–1.34)	1.00 (0.83–1.20)	1.26 (0.89–1.79)	1.11 (0.59–2.09)	1.18 (1.03–1.35)	0.33
Breast, female ≥60 years	1.29 (0.63–2.64)	1.00 (0.83–1.20)	1.21 (0.95–1.53)	1.53 (1.10–2.13)	1.21 (1.06–1.36)	0.02

	BMI (kg/m <sup>2</sup> )				Trend ≥18.5 (kg/m <sup>2</sup> )	
	12.0–18.4	18.5–24.9	25.0–29.9	30.0–60.0	Per 5 units	
Cancer site	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	P <sub>trend</sub>
Female genital organs	1.63 (0.96–2.75)	1.00 (0.82–1.23)	1.21 (0.92–1.59)	2.32 (1.61–3.34)	1.32 (1.12–1.56)	0.0008
Ovaries	0.86 (0.27–2.75)	1.00 (0.75–1.33)	1.24 (0.86–1.78)	2.14 (1.33–3.47)	1.28 (1.03–1.59)	0.01
Uterus	1.21 (0.29–5.15)	1.00 (0.63–1.57)	1.07 (0.58–1.99)	1.77 (0.74–4.23)	1.38 (0.95–1.99)	0.33
Cervix	2.55 (1.33–4.89)	1.00 (0.68–1.47)	1.30 (0.74–2.27)	3.64 (1.75–7.56)	1.42 (1.01–2.00)	0.02
Prostate	1.39 (0.65–2.97)	1.00 (0.83–1.20)	1.51 (1.26–1.82)	1.49 (1.05–2.11)	1.22 (1.03–1.45)	0.01
Bladder	1.48 (0.75–2.92)	1.00 (0.79–1.27)	1.06 (0.77–1.46)	0.53 (0.23–1.20)	1.00 (0.76–1.33)	0.46
Kidney	0.77 (0.18–3.22)	1.00 (0.74–1.34)	1.21 (0.86–1.72)	1.67 (0.94–2.96)	1.23 (0.93–1.63)	0.14
Brain and nervous system	1.19 (0.54–2.59)	1.00 (0.82–1.21)	0.96 (0.75–1.24)	0.89 (0.55–1.45)	0.93 (0.75–1.15)	0.67
Haematological cancers	1.42 (0.88–2.31)	1.00 (0.88–1.14)	1.13 (0.96–1.32)	1.19 (0.90–1.57)	1.11 (0.98–1.27)	0.16
Lymphoma	1.85 (0.99–3.46)	1.00 (0.82–1.22)	1.17 (0.92–1.47)	0.84 (0.52–1.36)	0.99 (0.81–1.21)	0.97
Myeloma	1.64 (0.48–5.56)	1.00 (0.72–1.39)	0.98 (0.64–1.49)	1.14 (0.58–2.21)	1.06 (0.76–1.47)	0.76
Leukaemia	0.82 (0.29–2.26)	1.00 (0.81–1.23)	1.14 (0.89–1.47)	1.65 (1.10–2.47)	1.27 (1.05–1.54)	0.047

Models stratified by study and sex. BMI=body-mass index. UADT=upper aerodigestive tract. \*For number of events in each BMI category see webtable 4. †All cancers after excluding lung and UADT.

**Webtable 4: Site-specific number of cancer deaths in the study sample by body mass index category before ( $n = 424\ 519$ ) and after left censoring at 3 years ( $n = 401\ 215$ ) in the Asia Pacific Cohort Studies Collaboration**

Cancer site	Left cens.	Body mass index (kg/m <sup>2</sup> )				
	years	12.0-18.4	18.5-22.9	23.0-24.9	25.0-29.9	30-60
All Cancer	0	476	2656	1441	2031	607
	3	276	1790	975	1388	443
UADT	0	40	179	61	91	17
	3	20	125	42	54	12
Oesophagus	0	24	100	36	57	12
	3	15	73	26	30	7
Oropharynx & larynx	0	16	79	25	34	5
	3	5	52	16	24	5
Stomach	0	75	403	174	171	32
	3	47	264	108	120	22
Large intestine	0	18	176	117	255	102
	3	11	134	85	194	79
Colon	0	8	104	76	168	73
	3	5	82	58	128	57
Rectum	0	8	104	76	168	73

Cancer site	Left cens.	Body mass index (kg/m <sup>2</sup> )				
	years	12.0-18.4	18.5-22.9	23.0-24.9	25.0-29.9	30-60
	3	5	82	58	128	57
Liver	0	57	351	179	165	22
	3	33	205	97	94	14
Pancreas	0	11	114	65	90	21
	3	9	80	47	68	17
Lung	0	149	611	283	334	101
	3	72	383	178	193	64
Skin, melanoma	0	2	15	27	30	14
	3	2	9	19	22	12
Breast, female	0	9	104	63	98	50
	3	4	74	48	68	39
Female genital organs	0	16	60	35	51	36
	3	9	46	23	43	30
Uterus	0	2	10	9	10	6
	3	2	7	6	9	3
Cervix	0	11	19	9	12	9
	3	7	16	6	9	8

Cancer site	Left cens. years	Body mass index (kg/m <sup>2</sup> )				
		12.0-18.4	18.5-22.9	23.0-24.9	25.0-29.9	30-60
Ovaries	0	3	30	16	29	21
	3	0	22	11	25	19
Prostate	0	8	49	41	143	37
	3	5	40	34	105	27
Bladder	0	11	30	30	43	6
	3	5	18	20	29	5
Kidney	0	2	31	11	35	14
	3	2	19	10	27	9
Brain & nervous system	0	7	58	42	66	18
	3	6	44	31	46	14
Hematologic cancers	0	19	116	89	172	58
	3	11	79	60	119	43
Lymphoma	0	12	52	38	80	19
	3	5	32	22	53	13
Myeloma	0	3	12	19	25	10
	3	3	11	16	19	9
Leukaemia	0	4	52	32	67	29

Cancer site	Left cens.	Body mass index (kg/m <sup>2</sup> )				
	years	12.0-18.4	18.5-22.9	23.0-24.9	25.0-29.9	30-60
	3	3	36	22	47	21

**Webtable 5: Site-specific number of cancer deaths in the study sample by region and body mass index category after left censoring at 3 years ( $n = 401\ 215$ ) in the Asia Pacific Cohort Studies Collaboration**

Cancer site	Region*	Body mass index (kg/m <sup>2</sup> )				
		12.0-18.4	18.5-22.9	23.0-24.9	25.0-29.9	30-60
All Cancer	ANZ	23	433	448	946	395
	Asia	253	1357	527	442	48
UADT	ANZ	0	25	18	31	10
	Asia	20	100	24	23	2
Oesophagus	ANZ	0	8	13	17	6
	Asia	15	65	13	13	1
Oropharynx, larynx	ANZ	0	17	5	14	4
	Asia	5	35	11	10	1
Stomach	ANZ	2	12	26	42	16
	Asia	45	252	82	78	6
Large intestine	ANZ	2	62	54	163	73
	Asia	9	72	31	31	6
Liver	ANZ	0	8	6	19	6
	Asia	33	197	91	75	8
Pancreas	ANZ	0	14	26	52	15

Cancer site	Region *	Body mass index (kg/m <sup>2</sup> )				
		12.0-18.4	18.5-22.9	23.0-24.9	25.0-29.9	30-60
Lung	Asia	9	66	21	16	2
	ANZ	7	94	88	130	57
Skin, melanoma	Asia	65	289	90	63	7
	ANZ	1	9	19	20	12
Breast, female	Asia	1	0	0	2	0
	ANZ	3	42	35	57	37
Female genital organs	Asia	1	32	13	11	2
	ANZ	0	15	12	31	27
Prostate	Asia	9	31	11	12	3
	ANZ	1	28	27	101	26
Bladder	Asia	4	12	7	4	1
	ANZ	2	8	14	23	5
Kidney	Asia	3	10	6	6	0
	ANZ	0	8	7	23	7
Brain & nervous system	Asia	2	11	3	4	2
	ANZ	1	13	22	34	14
	Asia	5	31	9	12	0

Cancer site	Region *	Body mass index (kg/m <sup>2</sup> )				
		12.0-18.4	18.5-22.9	23.0-24.9	25.0-29.9	30-60
Hematologic cancers	ANZ	3	37	33	102	40
	Asia	8	42	27	17	3
Lymphoma	ANZ	2	15	12	44	12
	Asia	3	17	10	9	1
Myeloma	ANZ	1	6	12	16	8
	Asia	2	5	4	3	1
Leukaemia	ANZ	0	16	9	42	20
	Asia	3	20	13	5	1

\*ANZ = Australia and New Zealand (n = 91 952); Asia = mainland China, Hong Kong, Taiwan, Japan, South Korea, Singapore, and Thailand (n = 309 263)

**Webtable 6: Sex-specific age and smoking adjusted hazard ratios (HR) with 95% confidence intervals (CI) for cancer mortality according to body mass index after left censoring at 3 years ( $n = 401\ 215$ ) in the Asia Pacific Cohort Studies Collaboration. Models stratified by study and sex.**

Cancer site	Sex	Body mass index (kg/m <sup>2</sup> )						Trend > 18.5 (kg/m <sup>2</sup> )				
		18.5-24.9		25.0-29.9		30.0-60.0		< 25 vs. ≥ 25	Per 5 units			
		HR	95% CI	HR	95% CI	HR	95% CI		HR	95% CI	$P_{sex}^{\dagger}$	$P_{trend}$
All Cancer	Men	1.00	(0.94, 1.07)	0.96	(0.91, 1.02)	1.05	(0.92, 1.21)	0.41	0.99	(0.93, 1.05)	0.04	0.99
	Women	1.00	(0.92, 1.08)	0.98	(0.90, 1.07)	1.19	(1.03, 1.36)		1.08	(1.02, 1.15)		
All Cancer*	Men	1.00	(0.92, 1.08)	1.09	(1.02, 1.16)	1.18	(1.01, 1.38)	0.78	1.07	(1.00, 1.15)	0.57	0.03
	Women	1.00	(0.92, 1.09)	1.02	(0.93, 1.12)	1.25	(1.07, 1.45)		1.10	(1.03, 1.18)		
Upper aero-digestive	Men	1.00	(0.76, 1.31)	0.70	(0.53, 0.92)	0.64	(0.32, 1.31)	0.58	0.71	(0.54, 0.94)	0.26	0.07
	Women	1.00	(0.65, 1.53)	0.86	(0.50, 1.48)	0.81	(0.30, 2.22)**		0.94	(0.64, 1.38)		
Oesophagus	Men	1.00	(0.69, 1.45)	0.76	(0.51, 1.14)	0.80	(0.29, 2.20)**	0.78	0.86	(0.59, 1.25)	0.89	0.38
	Women	1.00	(0.60, 1.66)	0.89	(0.48, 1.66)	0.81	(0.25, 2.60)**		0.89	(0.57, 1.41)		
Oropharynx, larynx	Men	1.00	(0.67, 1.49)	0.64	(0.43, 0.95)	0.53	(0.19, 1.44)**	0.73	0.59	(0.39, 0.88)	0.16	0.09
	Women	1.00	(0.46, 2.20)	0.78	(0.26, 2.32)**	0.81	(0.11, 6.06)**		1.07	(0.51, 2.22)		
Stomach	Men	1.00	(0.82, 1.22)	0.95	(0.78, 1.16)	1.07	(0.63, 1.82)	0.25	1.13	(0.94, 1.36)	0.64	0.92
	Women	1.00	(0.77, 1.30)	1.30	(0.98, 1.73)	1.02	(0.46, 2.22)		1.05	(0.82, 1.35)		
Large intestine	Men	1.00	(0.79, 1.27)	1.52	(1.29, 1.78)	1.99	(1.45, 2.73)	0.06	1.21	(1.01, 1.44)	0.46	0.0003

Cancer site	Sex	Body mass index (kg/m <sup>2</sup> )						Trend > 18.5 (kg/m <sup>2</sup> )					
		18.5-24.9		25.0-29.9		30.0-60.0		< 25 vs. ≥ 25	Per 5 units				
		HR	95% CI	HR	95% CI	HR	95% CI		HR	95% CI	<i>P</i> <sub>sex</sub> <sup>†</sup>	<i>P</i> <sub>trend</sub>	
Colon	Women	1.00	(0.81, 1.24)	1.01	(0.80, 1.27)	1.28	(0.91, 1.78)		1.10	(0.94, 1.29)		0.31	
	Men	1.00	(0.74, 1.34)	1.28	(1.04, 1.58)	2.14	(1.50, 3.06)	0.21	1.29	(1.05, 1.60)	0.14	0.002	
Rectum	Women	1.00	(0.78, 1.29)	1.04	(0.80, 1.35)	1.08	(0.72, 1.63)		1.05	(0.87, 1.26)		0.73	
	Men	1.00	(0.67, 1.49)	1.88	(1.47, 2.40)	1.43	(0.72, 2.82)	0.18	1.03	(0.75, 1.41)	0.41	0.07	
Liver	Women	1.00	(0.66, 1.51)	0.85	(0.52, 1.39)	1.89	(1.05, 3.38)		1.23	(0.92, 1.64)		0.19	
	Men	1.00	(0.84, 1.19)	0.95	(0.76, 1.18)	1.33	(0.72, 2.46)	0.13	1.06	(0.87, 1.30)	0.39	0.86	
Pancreas	Women	1.00	(0.67, 1.49)	1.72	(1.20, 2.48)	0.76	(0.24, 2.45)	**	1.25	(0.91, 1.72)		0.39	
	Men	1.00	(0.71, 1.40)	0.92	(0.69, 1.21)	0.55	(0.24, 1.25)	0.23	0.85	(0.63, 1.16)	0.12	0.26	
Lung	Women	-	(0.70, 1.42)	1.25	(0.88, 1.78)	1.32	(0.71, 2.44)		1.17	(0.91, 1.51)		0.34	
	Men	1.00	(0.87, 1.15)	0.66	(0.56, 0.77)	0.80	(0.58, 1.11)	0.31	0.80	(0.69, 0.92)	0.09	0.003	
Skin, melanoma	Women	1.00	(0.81, 1.23)	0.78	(0.60, 1.02)	0.93	(0.62, 1.41)		0.97	(0.81, 1.16)		0.40	
	Men	1.00	(0.61, 1.64)	0.66	(0.42, 1.03)	0.59	(0.24, 1.44)	**	0.35	(0.58, 1.44)	0.19	0.21	
Bladder	Women	1.00	(0.50, 1.99)	0.60	(0.23, 1.60)	2.10	(0.98, 4.50)		1.38	(0.91, 2.08)		0.25	
	Men	1.00	(0.62, 1.62)	1.46	(1.04, 2.05)	0.72	(0.23, 2.27)	**	0.10	(0.69, 1.57)	0.67	0.74	
Kidney	Women	1.00	(0.48, 2.09)	0.32	(0.08, 1.26)	**	0.70	(0.17, 2.85)	**	1.22	(0.67, 2.23)		0.37
	Men	1.00	(0.56, 1.78)	1.59	(1.06, 2.39)	2.56	(1.17, 5.62)	0.37	1.51	(1.01, 2.27)	0.10	0.05	

Cancer site	Sex	Body mass index (kg/m <sup>2</sup> )						Trend > 18.5 (kg/m <sup>2</sup> )					
		18.5-24.9		25.0-29.9		30.0-60.0		< 25 vs. ≥ 25		Per 5 units			
		HR	95% CI	HR	95% CI	HR	95% CI	<i>P</i> <sub>sex</sub> <sup>†</sup>	HR	95% CI	<i>P</i> <sub>sex</sub> <sup>†</sup>	<i>P</i> <sub>trend</sub>	
Brain & nervous system	Women	1.00	(0.49, 2.02)	1.17	(0.61, 2.27)	0.63	(0.15, 2.61)	**		0.85	(0.48, 1.48)		0.74
	Men	1.00	(0.69, 1.45)	0.94	(0.69, 1.29)	1.05	(0.53, 2.07)		0.97	0.90	(0.64, 1.27)	0.55	0.98
Hematologic cancers	Women	1.00	(0.63, 1.58)	0.95	(0.57, 1.60)	0.92	(0.37, 2.26)	**		1.05	(0.73, 1.52)		0.85
	Men	1.00	(0.75, 1.34)	1.33	(1.09, 1.63)	1.49	(0.97, 2.29)		0.34	1.22	(0.98, 1.51)	0.51	0.08
Lymphoma	Women	1.00	(0.74, 1.34)	1.03	(0.76, 1.39)	1.13	(0.72, 1.77)			1.10	(0.90, 1.35)		0.69
	Men	1.00	(0.62, 1.62)	1.66	(1.23, 2.25)	1.02	(0.44, 2.34)		0.35	1.07	(0.75, 1.52)	0.99	0.45
Myeloma	Women	1.00	(0.63, 1.58)	1.08	(0.69, 1.70)	0.97	(0.45, 2.09)			1.07	(0.77, 1.48)		0.97
	Men	1.00	(0.53, 1.90)	1.05	(0.64, 1.71)	1.39	(0.56, 3.45)	**	0.57	1.11	(0.67, 1.86)	0.76	0.62
Leukaemia	Women	1.00	(0.52, 1.93)	0.65	(0.28, 1.55)	1.06	(0.39, 2.89)	**		0.99	(0.60, 1.65)		0.89
	Men	1.00	(0.64, 1.56)	1.20	(0.87, 1.66)	2.00	(1.09, 3.66)		0.84	1.42	(1.03, 1.96)	0.42	0.10
	Women	1.00	(0.62, 1.61)	1.17	(0.74, 1.85)	1.33	(0.67, 2.62)			1.19	(0.87, 1.62)		0.48

\*All cancers after excluding lung and upper aero-digestive tract cancers. \*\*HR based on ≤ 5 events. †P-value of interaction term.

**Webappendix: List of the Asia Pacific Cohort Studies Collaboration (APCSC) Executive Committee members and participating studies with principal collaborators  
APCSC Executive Committee**

M. Woodward (Chair), X. Fang, D.F. Gu, R. Huxley, Y. Imai, H.C. Kim, T.H. Lam, W.H. Pan, A. Rodgers, I. Suh, H. Ueshima

**Participating Studies and Principal Collaborators in APCSC**

Aito Town: A. Okayama, H. Ueshima, H. Maegawa; Akabane: M. Nakamura, N. Aoki; Anzhen02: Z.S. Wu; Anzhen: C.H. Yao, Z.S. Wu; Australian Longitudinal Study of Aging: Mary Luszcz; Australian National Heart Foundation: T.A. Welborn; Beijing Aging: Z. Tang; Beijing Steelworkers: L.S. Liu, J.X. Xie; Blood Donors' Health: R. Norton, S. Ameratunga, S. MacMahon, G. Whitlock; Busselton: M.W. Knuiman; Canberra-Queanbeyan: H. Christensen; Capital Iron and Steel Company: X.G. Wu; CISCH: J. Zhou, X.H. Yu; Civil Service Workers: A. Tamakoshi; CVDFACTS: W.H. Pan; East Beijing: Z.L. Wu, L.Q. Chen, G.L. Shan; Electricity Generating Authority of Thailand: P. Sritara; Fangshan: D.F. Gu, X.F. Duan; Fletcher Challenge: S. MacMahon, R. Norton, G. Whitlock, R. Jackson; Guangzhou: Y.H. Li; Guangzhou Occupational: T.H. Lam, C.Q. Jiang; Hisayama: Y. Kiyohara, H. Arima, M. Iida; Hong Kong: J. Woo, S.C. Ho; Huashan: Z. Hong, M.S. Huang, B. Zhou; Kinmen: J.L. Fuh; Konan: H. Ueshima, Y. Kita, S.R. Choudhury; KMIC: I. Suh, S.H. Jee, I.S. Kim; Melbourne: G.G. Giles; Miyama: T. Hashimoto, K. Sakata; Newcastle: A. Dobson; Ohasama: Y. Imai, T. Ohkubo, A. Hozawa; Perth: the late K. Jamrozik, M. Hobbs, R. Broadhurst; Saitama: K. Nakachi; Seven Cities: X.H. Fang, S.C. Li, Q.D. Yang; Shanghai Factory Workers: Z.M. Chen; Shibata: H. Tanaka; Shigaraki Town: Y. Kita, A. Nozaki, H. Ueshima; Shirakawa: H. Horibe, Y. Matsutani, M. Kagaya; Singapore Heart: K. Hughes, J. Lee; Singapore NHS92: D. Heng, S.K. Chew; Six Cohorts: B.F. Zhou, H.Y. Zhang; Tanno/Soubetsu: K. Shimamoto, S. Saitoh; Tianjin: Z.Z. Li, H.Y. Zhang; Western Australia AAA Screenees: P. Norman, the late K. Jamrozik; Xi'an: Y. He, T.H. Lam; Yunnan: S.X. Yao.